公开(公告)号：EP1549760A2

公开(公告)日：2005-07-06

申请号：EP02750377.0

申请日：2002-07-31

申请人： Rigel Pharmaceuticals, Inc.

发明人： DEMO, Susan ,  HITOSHI, Yasumichi ,  JENKINS, Yonchu

IPC分类号： C12Q1/68 ,  C12Q1/48 ,  G01N33/53 ,  A61K39/395 ,  A61K48/00 ,  A61K7/46

CPC分类号： G01N33/57484 ,  A61K38/00 ,  A61K2039/505 ,  G01N2333/912

摘要： The present invention relates to regulation of cellular proliferation. More particularly, the present invention is directed to nucleic acids encoding SAK, which is a protein kinase involved in modulation of cellular proliferation and cell cycle regulation. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions, antibodies, peptides, cyclic peptides, nucleic acids, RNAi, antisense nucleic acids, and ribozymes, that modulate cell cycle regulation and cellular proliferation via modulation of SAK; as well as to the use of expression profiles and compositions in diagnosis and therapy related to cell cycle regulation and modulation of cellular proliferation, e.g., for treatment of cancer and other diseases of cellular proliferation.

公开(公告)号：EP1237916B1

公开(公告)日：2005-03-09

申请号：EP00979200.3

申请日：2000-11-17

申请人： Rigel Pharmaceuticals, Inc.

发明人： LUO, Ying ,  XU, Xiang ,  LEO, Cindy ,  HUANG, Betty ,  SHEN, Mary

IPC分类号： C07K14/47

CPC分类号： C07K14/4747 ,  A61K38/00

摘要： The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also, provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

公开(公告)号：EP1471915A2

公开(公告)日：2004-11-03

申请号：EP03707654.4

申请日：2003-01-31

申请人： Rigel Pharmaceuticals, Inc.

发明人： SINGH, Rajinder ,  ARGADE, Ankush ,  PAYAN, Donald, G. ,  MOLINEAUX, Susan ,  HOLLAND, Sacha, J. ,  CLOUGH, Jeffrey ,  KEIM, Holger ,  BHAMIDIPATI, Somasekhar ,  SYLVAIN, Catherine ,  LI, Hui ,  ROSSI, Alexander, B.

IPC分类号： A61K31/505 ,  C07D239/28

CPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5383 ,  A61K31/5395 ,  A61K31/551 ,  A61K45/06 ,  C07D239/48 ,  C07D265/36 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D495/04 ,  C07D498/04 ,  C07D498/14 ,  C07F5/027

摘要： The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signalling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signalling cascades.

公开(公告)号：EP1412745A2

公开(公告)日：2004-04-28

申请号：EP02723908.6

申请日：2002-04-18

申请人： Rigel Pharmaceuticals, Inc.

发明人： CHU, Peter ,  JIANG, Yingping ,  LI, Congfen ,  LIAO, X., Charlene ,  MASUDA, Esteban ,  PARDO, Jorge ,  SPENCER, Colin ,  ZHAO, Haoran

IPC分类号： G01N33/53 ,  G01N33/566

CPC分类号： C07K14/705 ,  G01N33/56972 ,  G01N2333/4703 ,  G01N2500/10

摘要： The present invention relates to regulation of lymphocyte activa tion and migration. More particularly, the present invention is directed to nucleic acids encoding EDG family GPCR proteins, e.g., EDG-1, 2, 3, 4, 5, 6, 7, or 8, which are involved in modulation of lymphocyte activation and migration. The invention further relates to methods for identifying and using agents, including small organic molecules, antibodies, peptides, cyclic peptides, nucleic acids, antisense nucleic acids, sphingolipid analogs, and ribozymes, that modulate lymphocyte activation or migration via modulation of EDG GPCRs and EDG related signal transduction; as well as to the use of expression profiles and compositions in diagnosis and therapy related to lymphocyte activation and suppression, and lymphocyte migration.

公开(公告)号：EP1363127A3

公开(公告)日：2004-03-24

申请号：EP03019052.4

申请日：1999-04-16

申请人： Rigel Pharmaceuticals, Inc.

发明人： Fisher, Joseph ,  Lorens, James ,  Payan, Donald ,  Rossi, Alexander

IPC分类号： G01N33/50 ,  G01N33/533 ,  G01N33/569

CPC分类号： G01N33/5011 ,  C12N15/1079 ,  G01N33/5008 ,  G01N33/5014 ,  G01N33/502 ,  G01N33/5044 ,  G01N33/56966 ,  G01N2333/43595 ,  G01N2333/4718

摘要： The invention relates to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.

公开(公告)号：EP1238064A2

公开(公告)日：2002-09-11

申请号：EP00978757.3

申请日：2000-11-16

申请人： Rigel Pharmaceuticals, Inc.

发明人： LUO, Ying ,  YU, PeiWen ,  SHEN, Mary ,  HUANG, Betty

IPC分类号： C12N9/12

CPC分类号： C12N9/1205 ,  C07K14/4738 ,  C07K16/18

摘要： The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.

公开(公告)号：EP1161442A2

公开(公告)日：2001-12-12

申请号：EP00902456.3

申请日：2000-01-20

申请人： Rigel Pharmaceuticals, Inc.

发明人： LUO, Ying

IPC分类号： C07K14/47 ,  C12N15/10 ,  C07K16/18 ,  C12N15/12 ,  G01N33/50

CPC分类号： C07K14/435 ,  A61K38/00

摘要： The present invention is directed to novel polypeptides such as the Exo protein and related molecules which have an effect on or are related to exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are method for identifying novel compositions which mediated Exo bioactivity, and the use of such compositions in diagnosis and treatment of disease.

公开(公告)号：EP1056855A2

公开(公告)日：2000-12-06

申请号：EP99908382.7

申请日：1999-02-23

申请人： Rigel Pharmaceuticals, Inc.

发明人： FISHER, Joseph ,  LORENS, James ,  ANDERSON, David ,  LUO, Ying ,  HUANG, Betty ,  SHEN, Mary

IPC分类号： C12N15/12 ,  C12N5/10 ,  C07K14/47 ,  C07K16/18 ,  G01N33/50

CPC分类号： C07K14/4703

摘要： The present invention is directed to novel exocytotic polypeptides, such as Exo1 and Exo2 polypeptides and related molecules, which have an inhibitory effect on exocytosis and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate exocytotic polypeptide bioactivity, and the use of such compositions in diagnosis and treatment of disease.

公开(公告)号：EP4399208A1

公开(公告)日：2024-07-17

申请号：EP22867909.8

申请日：2022-08-26

申请人： Rigel Pharmaceuticals, Inc.

发明人： MARKOVTSOV, Vadim ,  MASUDA, Esteban

IPC分类号： C07D405/04 ,  C07D405/14 ,  C07D413/04 ,  C07D417/04 ,  C07D417/14

CPC分类号： Y02A50/30 ,  C07D405/14 ,  C07D417/14 ,  C07F9/65583 ,  A61P1/00 ,  C07H19/052

公开(公告)号：EP4248975A2

公开(公告)日：2023-09-27

申请号：EP23181764.4

申请日：2019-05-02

申请人： Rigel Pharmaceuticals, Inc.

发明人： MASUDA, Esteban ,  SHAW, Simon ,  TAYLOR, Vanessa ,  BHAMIDIPATI, Somasekhar

IPC分类号： A61K31/553

摘要： Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP 1-associated disease or condition.